Immune checkpoint inhibitor-related pneumonitis
Conditions
Interventions
Observation group:None
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years, male or female; 2.Histologically or cytologically confirmed non-small cell lung cancer (NSCLC); 3.Planned to receive immune checkpoint inhibitor (ICI) therapy, including monotherapy or combination therapy; 4.Complete baseline data available, including demographic information and medical history of respiratory diseases; 5.Complete baseline laboratory tests (complete blood count, liver and kidney function, IL-6, IL-8, IL-10, antinuclear antibody panel, etc.), pulmonary function tests, and imaging data (chest CT); 6.Voluntary participation with signed written Informed Consent Form (ICF); 7.Able to understand the study requirements, and willing and able to comply with scheduled follow-up visits.
Exclusion criteria
Exclusion criteria: 1.Definitively diagnosed with immune checkpoint inhibitor-related pneumonitis (CIP) prior to enrollment; 2.Judged by the investigator to have poor compliance and be unable to complete regular follow-ups.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and Severity Grade of Immune Checkpoint Inhibitor-Related Pneumonitis (CIP); | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Other Immune-Related Adverse Events (irAEs);Changes in Pulmonary Function (Changes from Baseline in FEV1, FVC, and DLCO);Time to CIP Onset; | — |
Countries
China
Contacts
Public ContactXu Yan
Peking Union Medical College Hospital
Outcome results
None listed